Loading ...
a pivotal trial 's EndoBarrier devicedesignedfor treating patients with type 2 diabetes and obesity
the gastrointestinal absorption of glucose ... reduces food intakepreventingbody weight gain in obese patients with type 2 diabetes
The team headed by physician scientist Matthias Tschop ( Helmholtz Diabetes Center at HMGU and Metabolic Diseases Chair at TUM ) and peptide chemist Richard DiMarchi ( Indiana University ... almost a decadeto inventimproved therapeutics for type 2 diabetes and obesity
the ability of the α - glucosidase inhibitor acarbose ( Precoseto preventtype 2 diabetes in overweight and obese patients with IGT.27
exercise instructioncan resultin weight reduction in obese patients with type 2 diabetes
to control type 2 diabetes over time compared with intensive medical therapy alone ,resultingin superior glycemic control and weight reduction for obese patients with uncontrolled type 2 diabetes
the druginfluencesinsulin sensitivity in patients with type 2 diabetes and obesity
U.S. IDE trial of Endobarrieris designedfor patients diagnosed with type 2 diabetes and obesity
its non - surgical devicedesignedto treat patients with obesity and uncontrolled type 2 diabetes
to a sustained reduction in weight , improvement in glycemic control , and decrease in cardiovascular risk compared to a medical diabetes and weight management programleadsto a sustained reduction in weight , improvement in glycemic control , and decrease in cardiovascular risk compared to a medical diabetes and weight management program
to a sustained reduction in weight , improvement in glycaemic control , and decrease in cardiovascular risk compared to a medical diabetes and weight management programmeleadsto a sustained reduction in weight , improvement in glycaemic control , and decrease in cardiovascular risk compared to a medical diabetes and weight management programme
to a sustained reduction in weight , improvement in glycaemic control , and decrease in cardiovascular risk compared to a medical diabetes and weight management programleadsto a sustained reduction in weight , improvement in glycaemic control , and decrease in cardiovascular risk compared to a medical diabetes and weight management program
metabolic risk(passive) caused bymetabolic risk
in better glucose control than did medical therapyresultedin better glucose control than did medical therapy
a condition called non - proliferative diabetic retinopathycan causea condition called non - proliferative diabetic retinopathy
in significant weight loss and reductions in HbA1c ... according to the dataresultin significant weight loss and reductions in HbA1c ... according to the data
insulin induced CRPC pathwaysto preventinsulin induced CRPC pathways